重视多发性骨髓瘤规范化诊治

黄晓军; 路瑾

doi:10.3969/j.issn.1000-8179.20140932

重视多发性骨髓瘤规范化诊治

doi: 10.3969/j.issn.1000-8179.20140932

黄晓军^,,
路瑾

北京大学人民医院，北京大学血液病研究所（北京市 100044）

基金项目:

科技部重大专项 2012ZX09303019

国家自然科学基金项目 81372535

详细信息

作者简介:
黄晓军教授，博士生导师。现任北京大学人民医院血液病研究所所长、北京大学医学部血液病学系主任，造血干细胞移植治疗血液病北京市重点实验室主任，北大清华生命中心临床PI。国家杰出青年基金获得者，教育部长江特聘教授，兼任亚太血液联盟主席，Asian Cellular Therapy Organization候任主席，第九届中华医学会血液学分会主任委员，中国医师协会血液科医师分会副会长，卫生部海峡两岸医药卫生交流协会血液专家委员会主任委员，中国病理生理学会实验血液学专业委员会副主任委员兼秘书长，国家自然科学基金委员会第十三届医学科学部专家评审组成员，Annals of Hematology期刊高级编委；BMT等多个期刊编委及主编。自1989年开始从事血液病临床及实验研究，在常见血液病的诊断和治疗方面具有丰富的经验。负责并承担NSFC、“863”、“985”、卫生部及教育部等多项基金。国内外发表论文近300余篇，综述25篇，专著20部

通讯作者:
黄晓军 xjhrm@medmail.com.cn

计量
- 文章访问数: 53
- HTML全文浏览量: 24
- PDF下载量: 16
- 被引次数: 0
出版历程
- 收稿日期: 2014-05-01
- 修回日期: 2014-05-20
- 刊出日期: 2014-07-15

The standardization of diagnosis and treatment of multiple myeloma

HUANG Xiaojun^,,
LU Jin

Peking University Institute of Hematology, People's Hospital, Beijing 100044, China

Funds:

Major Project of National Science and Technology "Creation of Major New Drugs" 2012ZX09303019

National Natural Science Foundation of China 81372535

More Information

Corresponding author: Xiaojun HUANG; E-mail: xjhrm@medmail.com.cn

摘要

摘要: 随着多发性骨髓瘤的诊断技术以及治疗手段的不断提升，该疾病的诊断标准以及疗效评判标准也在不断变化，规范化的诊断以及治疗是个性化治疗的基石。目前国内仍存在诊断、疗效评估以及治疗方面的不规范，例如用血清蛋白电泳而非免疫固定电泳进行诊断，用免疫球蛋白总量来代替M蛋白，依赖形态来判定浆细胞的良恶性，将部分淋巴细胞疾病误诊为骨髓瘤，对预后分层重视不足，自体造血干细胞移植的比例偏低，疗效评估用免疫球蛋白总量而非M蛋白进行评估等。规范化的诊治，才可使国内外的交流达成一致，并在统一平台上完成临床的合作。
- 多发性骨髓瘤 /
- 规范化诊断 /
- 规范化治疗
Abstract: The criteria for diagnosis and assessment of therapeutic effects has changed with the rapid development in diagnostic technology and treatment for multiple myeloma (MM). The standardized diagnosis and treatment are the cornerstone of individualized therapy. At present, standardization is lacking in MM diagnosis and treatment in China. In China, serum protein electrophoresis is used but not immunofixation, immunoglubin is used instead of M protein for diagnosis, morphology of the plasma cell is used to determine malignancy of the plasma cell, and some lymphomas are misdiagnosed as MM. The prognostic stratification is overshadowed and the number of patients who received autologous transplantation was much lower compared with other countries. The standardization of the diagnosis and treatment criteria in China will ensure better communication with other countries about MM and promote cooperation.
- multiple myeloma /
- standardized diagnosis /
- standardized treatment
注释:
专栏寄语:
1) 中国抗癌协会血液肿瘤专业委员会常委张翼鷟教授

1) ——教育部长江学者特聘教授黄晓军教授

1) 多发性骨髓瘤是血液系统常见的恶性肿瘤，由于其临床表现多种多样，很容易被误诊或漏诊，近年来随着诊疗水平和技术的进步，血液专科接诊的骨髓瘤患者明显增多，多发性骨髓瘤已经成为恶性血液肿瘤中最重要的病种之一，但由于该病患者以中老年人为主及目前治疗手段的局限，其长期缓解率、生存率并不乐观。针对骨髓瘤开展合理的个体化诊疗是血液科医生面临的重要挑战。我国目前针对骨髓瘤的诊断和治疗正逐渐与国际接轨，自体干细胞移植已成为高危骨髓瘤患者常规巩固治疗。国际上针对骨髓瘤的新药层出不穷，相关临床试验也如火如荼地展开，而这些新药对我国骨髓瘤患者的疗效尚须我们开展多中心临床研究进一步验证。我国骨髓瘤诊疗需要结合国情，参考国际指南，开辟一条更经济实用且合理的道路。《中国肿瘤临床》期刊特开辟“多发性骨髓瘤”专栏，诚邀我国多发性骨髓瘤领域的知名专家学者撰稿，发布相关临床和基础研究进展和诊疗策略。希望通过该专栏为血液肿瘤、放疗及病理等专业人员提供更完善、更便利的交流平台，推动我国多发性骨髓瘤研究成果的临床转化，造福广大患者。

HTML全文

参考文献(15)

[1]	中国多发性骨髓瘤工作组.中国多发性骨髓瘤诊治指南[J].中华内科杂志, 2008, 47(10):869-872. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk200810035 Multiple myeloma working group in China. diagnosis and treatment guideline on Multiple myeloma[J]. Chin J Intern Med, 2008, 47(10):869-872. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk200810035
[2]	路瑾, 黄晓军.三种诊断标准对多发性骨髓瘤诊断的对比研究[J].中华内科杂志, 2011, 51(2):114-116. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk201202011 Lu J, Huang XJ. A comparative analysis of three diagnostic criteria for multiple myeloma[J]. Chin J Intern Med, 51(2):114-116. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk201202011
[3]	中国医师协会血液科医师分会, 中华医学会血液学分会, 中国多发性骨髓瘤工作组.中国多发性骨髓瘤诊治指南(2013年修订) [J].中华内科杂志, 2013, 52(9): 791-795. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk201309028 The Chinese medical doctor association branch of haematology department physicians, Hematology branch of Chinese Medical Association, Multiple myeloma working group in China.diagnosis and treatment guideline on Multiple myeloma(revised in 2013)[J]. Chin J Intern Med, 2013, 52(9):791-795. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhnk201309028
[4]	Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1[J]. Blood, 2011, 117(18):4691-4695. doi: 10.1182/blood-2010-10-299487
[5]	Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013[J]. Mayo Clin Proc, 2013, 88(4):360-376. doi: 10.1016/j.mayocp.2013.01.019
[6]	Hose D, Seckinger A, Jauch A, et al. The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification[J]. Srp Arh Celok Lek, 2011, 139(suppl 2):84-89. http://cn.bing.com/academic/profile?id=a33577816760f531dcc05e24c952eccc&encoded=0&v=paper_preview&mkt=zh-cn
[7]	Avet-Loiseau H, Durie BG, Cavo M, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project[J]. Leukemia, 2013, 27(3):711-717. doi: 10.1038/leu.2012.282
[8]	Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma[J]. J Clin Oncol, 2005, 23(15):3412-3420. doi: 10.1200/JCO.2005.04.242
[9]	Snozek CL, Katzmann JA, Kyle RA, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system[J]. Leukemia, 2008, 22(10):1933-1937. doi: 10.1038/leu.2008.171
[10]	Bradwell A, Harding S, Fourrier N, et al. Prognostic utility of intact immunoglobulin Ig'kappa/Ig'lambda ratios in multiple myeloma patients[J]. Leukemia, 2013, 27(1):202-207. doi: 10.1038/leu.2012.159
[11]	Waheed S, Shaughnessy JD, van Rhee F, et al. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols[J]. Cancer, 2011, 117(5):1001-1009. doi: 10.1002/cncr.25535
[12]	Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma[J]. Blood, 2012, 119(13): 3003-3015. doi: 10.1182/blood-2011-11-374249
[13]	Rajkumar SV. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma[J]Hematology Am Soc Hematol Educ Program, 2012, 2012:354-361. doi: 10.1182/asheducation.V2012.1.354.3798330
[14]	Paiva B, Martinez-Lopez J, Vidriales MB, et al. Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma[J]. J Clin Oncol, 2011, 29(12):1627-1633. doi: 10.1200/JCO.2010.33.1967
[15]	Korthals M, Sehnke N, Kronenwett R, et al. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma[J]. Biol Blood Marrow Transplant, 2013, 19(7): 1109-1115. doi: 10.1016/j.bbmt.2013.04.025